0001104659-17-041906.txt : 20170627
0001104659-17-041906.hdr.sgml : 20170627
20170627215621
ACCESSION NUMBER: 0001104659-17-041906
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170623
FILED AS OF DATE: 20170627
DATE AS OF CHANGE: 20170627
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics Plc
CENTRAL INDEX KEY: 0001703287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 6108166640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Plc
DATE OF NAME CHANGE: 20170407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rowland Charles A Jr
CENTRAL INDEX KEY: 0001383292
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38132
FILM NUMBER: 17933634
MAIL ADDRESS:
STREET 1: 3338 LANCASHIRE RD
CITY: FURLONG
STATE: PA
ZIP: 18925
4
1
a4.xml
4
X0306
4
2017-06-23
0
0001703287
Nabriva Therapeutics Plc
NBRV
0001383292
Rowland Charles A Jr
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
1
0
0
0
Stock Option
2017-06-23
5
J
0
E
16000
0
A
2025-07-05
Ordinary Shares
16000
16000
D
Stock Option
2017-06-23
5
J
0
E
10100
0
A
2026-08-25
Ordinary Shares
10100
10100
D
The exercise price is 6.618 Euro.
Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.
The exercise price is 6.634 Euro.
This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
/s/ Gary L. Sender, by power of attorney
2017-06-27